Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tonix Pharm Holdings (NQ: TNXP )

0.5911 -0.0239 (-3.89%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tonix Pharm Holdings

< Previous 1 2 3 4 5 6 7 Next >
Sidoti & Company, LLC Announces Registration Now Open for March Small-Cap and May Micro-Cap Conferences
Via ACCESSWIRE
Tonix Pharmaceuticals Seeks To Bolster Its COVID-19 Pipeline With This New Acquisition
 
Via Benzinga
Tonix CEO Calls for New Class of Covid-19 Pre-Exposure and Therapeutic Antibodies for High-Risk Populations
Tonix mAb Technology Aims to Extend the Utility and Durability of COVID  Medicines for Immunocompromised and Other Risk Populations 
Via Benzinga
Tonix CEO Calls for New Class of Covid-19 Pre-Exposure and Therapeutic Antibodies for High-Risk Populations
by Faith Ashmore - Benzinga 
Via TheNewswire.com
Exposures COVID-19
Tonix CEO Calls for New Class of Covid-19 Pre-Exposure and Therapeutic Antibodies for High-Risk Populations
Tonix CEO Calls for New Class of Covid-19 Pre-Exposure and Therapeutic Antibodies for High-Risk Populations 
Via News Direct
Exposures COVID-19
Why Is Tonix Pharmaceuticals (TNXP) Stock Up 40% Today?
TNXP stock traders are in a bidding war today as Tonix announces a possible game-changer in Covid-19 treatment methodologies. 
Via InvestorPlace
Recap: Tonix Pharmaceuticals Q3 Earnings
Tonix Pharmaceuticals (NASDAQ:TNXP) reported its Q3 earnings results on Monday, November 7, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Crude Oil Rises Sharply; Adicet Bio Shares Plunge
U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 250 points on Monday 
Via Benzinga
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process. 
Via Benzinga
Why Is Reborn Coffee (REBN) Stock Up 34% Today?
Reborn Coffee (REBN) stock is heating up on Monday as investors take note of the California coffee company's shares with heavy trading. 
Via InvestorPlace
Why Is Harpoon Therapeutics (HARP) Stock Up 100%+ Today?
Harpoon Therapeutics (HARP) stock is taking off on Monday following the release of updated results from its myeloma drug candidate. 
Via InvestorPlace
Why Harpoon Therapeutics Shares Are Trading Higher By 97%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Gainers HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) shares jumped 165.7% to $1.4350 after jumping around 118% on Friday. HTG Molecular Diagnostics, last month, posted a Q3 loss of $0.41 per share. 
Via Benzinga
Why Tonix Pharmaceuticals Stock Is Rocketing Higher Today
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading higher Monday after the company announced the exclusive license of potential therapeutic or preventative humanized anti-SARS-CoV-2 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why Target Shares Are Trading Lower By 14%? Here Are 56 Stocks Moving In Wednesday's Mid-Day Session
Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares jumped 109% to $0.2115 after dipping around 48% on Tuesday. Fast Radius established a timeline for a Chapter 11 sale process. 
Via Benzinga
Threats For New Outbreak Looms, As Scientists Signal Deadly Monkeypox Variant Circulating In Central Africa
Researchers have warned that a dangerous monkeypox variant with a fatality rate as high as 10% is circulating in Central Africa, which could trigger new global outbreaks. After analyzing 1,463 cases... 
Via Benzinga
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease, announcing recently that it has gotten approval from Argentina’s regulators to begin a Phase ll... 
Via PressReach
Topics Cannabis
Exposures Cannabis
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – October 5, 2022 – A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease,... 
Via FinancialNewsMedia
Topics Cannabis
Exposures Cannabis
New Ways To Treat Long Covid Might Be Here Sooner Than Thought
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. The sponsored content team works to ensure... 
Via Benzinga
White House May Ask For $25B Emergency Funding For COVID-19, Monkeypox
 
Via Benzinga
Psychedelics Use Among Young Adults Reaches All-Time High
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 1, 2022 – Young adults are using more hallucinogens than ever. According to a National Institute of Health survey,... 
Via FinancialNewsMedia
Is Monkeypox Outbreak Cooling? Health Officials Says Virus Transmission Has Slowed
 
Via Benzinga
Looking Into Tonix Pharmaceuticals's Recent Short Interest
Tonix Pharmaceuticals's (NASDAQ:TNXP) short percent of float has risen 204.49% since its last report. The company recently reported that it has 2.36 million shares sold short,... 
Via Benzinga
Experts Cast Doubt On Dependence On Monkeypox Vaccine Amid Limited Trial Data, Supply Crunch
The only FDA-approved monkeypox vaccine from Bavarian Nordic A/S (OTC: BVNY) is in short supply. 
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
Tonix Pharmaceuticals Commences Mid-Stage Long COVID Study, Sees Interim Report In H1 2023
Tonix Pharmaceuticals (NASDAQ: TNXP) has initiated patient enrolment in the Phase 2 PREVAIL study of TNX-102 SL for patients with Long COVID syndrome (Long COVID). 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.